Jupiter Life Line Hospitals (JLHL) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
8 Jul, 2026Executive summary
Announced acquisition of a two-acre plot in Mira Road/Mira-Bhayandar for a new 300-bed multi-specialty hospital, marking the sixth facility and third in the MMR region.
Construction for the second Pune hospital (Bibvewadi) to begin in March 2025, with the first phase operational by 2028.
Indore hospital added 78 new beds, increasing capacity to 309, completed ahead of schedule.
Dombivli hospital's first phase expected to be operational by Q1 FY27.
Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, were approved by the Board on February 7, 2025.
Financial highlights
Q3 FY25 consolidated income: ₹3,206.38 million, up from ₹2,726.13 million in Q3 FY24; nine-month consolidated revenue: ₹9,303.41 million, up from ₹7,790.11 million year-over-year.
Q3 FY25 consolidated net profit: ₹525.14 million, up from ₹436.67 million in Q3 FY24; nine-month consolidated net profit: ₹1,486.27 million, up from ₹1,313.47 million year-over-year.
Q3 FY25 EBITDA: ₹76.4 crores, up 21.5% year-over-year; EBITDA margin at 23.7%.
9M FY25 total income: ₹934.8 crores, up 19.5% year-over-year; EBITDA: ₹218.3 crores, up 22%; PAT: ₹148.6 crores, up 13.2%.
Gross profit margin for 9MFY25 was 81.9%; EBITDA margin at 23.4%; PAT margin at 15.9%.
Outlook and guidance
Construction of the second Pune hospital to begin in March 2025; Dombivli hospital phase 1 to be operational by Q1 FY27.
Mira Road hospital planned for 2029 completion.
New greenfield hospitals expected to be EBITDA negative in year one, break-even in year two, and positive in year three.
Expansion aligns with the medium-term goal of a 2,500-bed network, with continued focus on Western India.
Latest events from Jupiter Life Line Hospitals
- Revenue advanced, but H1 profit eased as capacity expansion moved ahead.JLHL
Q2 26/27 - FY2023 profit rose as hospital revenues grew and IPO preparations advanced.JLHL
Q4 22/23 - FY22 revenue and profit advanced as COVID costs coincided with hospital expansion plans.JLHL
Q4 21/22 - Flat FY21 revenue masked lower profit amid COVID-19 disruption.JLHL
Q4 20/21 - H1 income grew 19.8%, debt was repaid, and Indore reached EBITDA break-even.JLHL
Q2 23/24 - Occupancy climbed and debt was cleared, while PAT benefited from a deferred-tax credit.JLHL
Q1 23/24 - Q1 FY27 revenue grew 16.2% to ₹4,109.83 million, with margin pressure from expansion.JLHL
Q1 26/27 - Q1 FY25 saw strong revenue and EBITDA growth, digital accreditation, and capacity expansion.JLHL
Q1 24/25 - Q3 FY26 income and EBITDA rose, but PAT fell due to labor code; major hospital expansion underway.JLHL
Q3 25/26